COMPARATIVE ACTIVITY OF DOXORUBICIN AND ITS MAJOR METABOLITE, DOXORUBICINOL, ON V79/AP4 FIBROBLASTS - A MORPHOFUNCTIONAL STUDY

被引:12
作者
BERNARDINI, N
GIANNESSI, F
BIANCHI, F
DOLFI, A
LUPETTI, M
ZACCARO, L
MALVALDI, G
DELTACCA, M
机构
[1] UNIV PISA,DIPARTMENTO BIOMED,I-56100 PISA,ITALY
[2] UNIV PISA,IST FARMACOL,I-56100 PISA,ITALY
关键词
D O I
10.1016/0014-4800(91)90004-H
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Doxorubicin (DXR), an anthracycline antineoplastic drug, is mainly metabolized to the C-13 dihydroderivative doxorubicinol (DXR-ol), which displays cytotoxic activity on various cell lines. To better characterize the cytotoxic activity of this metabolite, we have studied the effect of DXR (0.1-10 μg/ml) or DXR-ol (1-100 μg/ml) on the transformed fibroblast cell line V79 AP4 by means of the clonogenic assay, cytofluorescence, and light and electron microscopy. Both DXR and DXR-ol displayed a dose-dependent inhibition of colony formation with an IC50 factor DXR-ol DXR of 19.5. A striking nuclear fluorescence was observed after DXR but not after DXR-ol. A low number of mitoses and a decrease in nucleoli staining affinity were the most evident alterations induced by DXR. Electron microscopy showed both nuclear and cytoplasmic changes in DXR treated cells: nucleolar segregation, cytoplasmic vacuoles, and mitochondrial swelling with dense needle-shaped material were observed. Exposure to formic acid confirmed the calcific nature of the mitochondrial bodies. Only the highest dose of DXR-ol brough about nuclear and cytoplasmic ultrastructural changes similar to those induced by DXR. Our data describe new in vitro findings on the cytotoxicity and morphological alterations induced by both DXR and DXR-ol, with a lower activity of DXR-ol against V79 AP4 fibroblasts. © 1991.
引用
收藏
页码:238 / 250
页数:13
相关论文
共 27 条
  • [1] BARBIERI B, 1987, CANCER RES, V47, P4001
  • [2] COMPARISON OF INTRACELLULAR DRUG RETENTION, DNA DAMAGE AND CYTO-TOXICITY OF DERIVATIVES OF DOXORUBICIN AND DAUNORUBICIN IN A HUMAN-COLON ADENOCARCINOMA CELL-LINE (LOVO)
    BELVEDERE, G
    SUARATO, A
    GERONI, C
    GIULIANI, FC
    DINCALCI, M
    [J]. BIOCHEMICAL PHARMACOLOGY, 1989, 38 (21) : 3713 - 3721
  • [3] BHUYAN BK, 1983, CANCER RES, V43, P5293
  • [4] FINE STRUCTURE OF EARLY CARTILAGE CALCIFICATION
    BONUCCI, E
    [J]. JOURNAL OF ULTRASTRUCTURE RESEARCH, 1967, 20 (1-2): : 33 - &
  • [5] BOUCEK RJ, 1987, J BIOL CHEM, V262, P15851
  • [6] CININERI G, 1990, IN PRESS ONCOLOGY
  • [7] COMPARATIVE CARDIOTOXICITY AND ANTITUMOR-ACTIVITY OF DOXORUBICIN (ADRIAMYCIN) AND 4'-DEOXYDOXORUBICIN AND THE RELATIONSHIP TO INVIVO DISPOSITION AND METABOLISM IN THE TARGET TISSUES
    CUMMINGS, J
    WILLMOTT, N
    MORE, I
    KERR, DJ
    MORRISON, JG
    KAYE, SB
    [J]. BIOCHEMICAL PHARMACOLOGY, 1987, 36 (09) : 1521 - 1526
  • [8] DISPOSITION KINETICS OF ADRIAMYCIN, ADRIAMYCINOL AND THEIR 7-DEOXYAGLYCONES IN AKR MICE BEARING A SUB-CUTANEOUSLY GROWING RIDGWAY OSTEOGENIC-SARCOMA (ROS)
    CUMMINGS, J
    MERRY, S
    WILLMOTT, N
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (04): : 451 - 460
  • [9] CARDIAC TOXICITY AND ANTITUMOR-ACTIVITY OF 4'-DEOXY-4'-IODO-DOXORUBICINOL
    DANESI, R
    MARCHETTI, A
    BERNARDINI, N
    LAROCCA, RV
    BEVILACQUA, G
    DELTACCA, M
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 (06) : 403 - 408
  • [10] CYTOFLUORESCENCE LOCALIZATION AND DISPOSITION OF DOXORUBICIN AND DOXORUBICINOL IN RAT CARDIAC TISSUE
    DANESI, R
    PAPARELLI, A
    BERNARDINI, N
    DELTACCA, M
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (07): : 1123 - 1131